ARTICLE | Clinical News
Versicor starts Phase II dalbavancin trial
May 22, 2001 7:00 AM UTC
VERS began an open-label Phase II trial of dalbavancin in 60 hospitalized patients with complicated skin and soft tissue infections caused by Gram-positive bacteria. VERS acquired exclusive rights in ...